IDEAYA Biosciences announced an Investor R&D Day in London on Nov. 16, 2026, focused on its MTAP/CDKN2A and KRAS development strategy in pancreatic cancer. The session will include new preclinical data and rational combination strategies addressing tumor heterogeneity and adaptive plasticity, with Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center featured. The company will also participate in four September investor conferences in Boston and New York, with Chairman and Chief Executive Officer Yujiro S. Hata and Chief Financial Officer Joshua Bleharski appearing in fireside chats. Live audio webcasts and 30-day replays will be available. IDEAYA said the release contains forward-looking statements subject to risks described in its U.S. Securities and Exchange Commission filings, including its Feb. 17, 2026, Form 10-K.